- 01A high CA-125 is usually not cancer
CA-125 is built to monitor an ovarian cancer that is already diagnosed. As a general test it raises false alarms constantly, because periods, endometriosis, fibroids, benign cysts, pregnancy, and any irritation of the abdominal lining all push it up. So a high CA-125 in a woman who still has periods is far more likely to be benign than cancer, and a clinician reads it next to your symptoms and imaging, never as a diagnosis on its own.
- 02Normal does not mean clear
CA-125 stays under the usual 35 U/mL cutoff in about half of early-stage ovarian cancers, so a normal result is not an all-clear. That is why it works as a monitoring tool next to a known diagnosis and fails as a screen for healthy women: a large trial of more than 200,000 average-risk women found screening with it did not lower ovarian cancer deaths.
CA-125 (cancer antigen 125) is a protein in your blood that doctors measure mainly to follow a diagnosed ovarian cancer through treatment and watch for its return, not to screen healthy women. 1 A high number usually is not cancer, and a normal number does not rule it out.
What is a CA-125 test?
A CA-125 test measures the level of cancer antigen 125, a protein made by many cells that line body cavities, including the surface of the ovaries and the peritoneum (the lining of your abdomen). It is a simple blood draw with no fasting needed, usually ordered on its own rather than bundled into a routine panel. Because both healthy cells and cancer cells make this protein, the number alone cannot say where it came from. 1
What CA-125 is for
CA-125 earns its keep after ovarian cancer is diagnosed. In a woman being treated for epithelial ovarian cancer (the most common type, which starts in the surface-lining cells), a falling CA-125 suggests treatment is working, and a rising one can be an early sign the cancer is returning. 2 That is monitoring a known disease, a very different job from finding cancer in someone who feels well.
Most tumor markers were built to watch a cancer that is already diagnosed, not to find one in a healthy person.
That rule holds for this whole family of blood tests, covered in tumor markers explained. CA-125 is a textbook example of it.
Normal CA-125 levels
Most labs use a cutoff around 35 U/mL (units per milliliter): under that is called the reference range, above it is flagged as raised. 2 The exact number varies by lab, so read your result against the range printed on your own report.
| Band | Level (U/mL) | What it usually means |
|---|---|---|
| Within range | Under about 35 | The common cutoff. Does not rule ovarian cancer out: about half of early-stage cancers sit under 35. 2 |
| Raised | About 35 to a few hundred | Very often benign, especially before menopause. A reason for context, not panic. |
| Markedly raised | Into the hundreds | More likely to prompt specialist (gynecologic-oncology) evaluation, especially after menopause with a mass on imaging. Still read with imaging and symptoms, never alone. |
Where an example CA-125 fallsU/mL
What causes a high CA-125 besides cancer?
This is why CA-125 fails as a general test. The list of benign causes is long, and many of them are common, particularly before menopause. 2
| Category | Examples |
|---|---|
| Benign gynecologic (common) | Menstruation, endometriosis, uterine fibroids, benign ovarian cysts, pelvic inflammatory disease |
| Benign, other | Pregnancy (especially the first trimester), liver disease and cirrhosis, pancreatitis, recent abdominal or pelvic surgery, and anything that irritates the peritoneum, the abdominal lining |
| Cancer-associated (less common) | Epithelial ovarian cancer, its main monitoring use, and sometimes cancers of the fallopian tube, uterine lining, and other abdominal organs |
Why routine screening is not recommended
Testing CA-125 in healthy, average-risk women sounds sensible and turns out not to help. It raises alarms in women who do not have cancer, leading to worry, more scans, and sometimes surgery on benign findings, while missing many real cancers because it stays normal in about half of early-stage disease. 2
The USPSTF recommends against screening for ovarian cancer in asymptomatic women.US Preventive Services Task Force, JAMA 2018
That recommendation covers women at average risk who have no symptoms. For women at high risk, such as those with a BRCA gene change (an inherited gene change that raises ovarian and breast cancer risk) or a strong family history, whether to test at all is a shared decision made with a specialist, not a routine. 4
How context changes what a raised value means
The same CA-125 number reads differently depending on where you are in life. Before menopause, benign sources are everywhere, so a mildly raised value is usually one of them. After menopause, most of those benign sources are gone, so a raised value carries more weight, though it is still interpreted with imaging and symptoms rather than treated as an answer. 2
| Before menopause | After menopause | |
|---|---|---|
| Benign elevations | Very common (periods, endometriosis, fibroids, cysts, pregnancy) | Less common; fewer everyday sources |
| A raised value more likely means | Usually a benign cause | Still often benign, but weighted more heavily |
| How it is read | With cycle timing, symptoms, and imaging | With imaging and symptoms; may prompt referral |
CA-125 is also rarely used alone here. Clinicians combine it with a pelvic ultrasound, your symptoms and exam, and sometimes other markers, and in a woman with a pelvic mass they may use a calculated risk score, such as the Risk of Malignancy Index (RMI) or ROMA (Risk of Ovarian Malignancy Algorithm), to decide whether to refer to a gynecologic oncologist. 2
How it is tested and how often
CA-125 is a routine blood draw with no fasting and no special prep, usually ordered specifically rather than bundled into a general panel. Insurance typically covers it when there is a medical reason, such as monitoring a diagnosed cancer or working up a pelvic mass, and it is often not covered as a screening test for women with no symptoms and average risk. During ovarian cancer treatment and follow-up, clinicians repeat it on a set schedule and watch the trend, since the direction it moves matters more than any single value.
Link · US Preventive Services Task ForceScreening for ovarian cancer: USPSTF recommendationThe task force's plain statement on why it recommends against ovarian cancer screening in average-risk women, and the evidence behind it.uspreventiveservicestaskforce.org
Citations
- National Cancer Institute, Tumor Markers in Common Use (2024)
- Cancer Antigen 125, StatPearls, NCBI Bookshelf (2023)
- Menon U et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), The Lancet 2021;397:2182-2193
- US Preventive Services Task Force, Screening for Ovarian Cancer: Recommendation Statement, JAMA 2018
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.